Results for tag: "Late Stage Chronic Kidney Disease Drugs"

The Late-Stage Chronic Kidney Disease (CKD) drugs market is a subsector within the broader therapeutic area of liver and kidney disorders drugs. This market comprises pharmaceutical treatments focused on alleviating symptoms, slowing disease progression, and improving the quality of life for patients with advanced stages of CKD. As kidneys lose their filtering ability in late-stage CKD, patients may experience various complications, including high blood pressure, anemia, bone disease, and cardiovascular disease. Treatment regimens often involve a combination of drugs that target these complications, as well as therapies directly addressing kidney function decline. In the context of liver and kidney disorders drugs, the late-stage CKD treatments are integral for managing the health of patients with diminished renal function, who may ultimately require renal replacement therapy, such as dialysis or kidney transplantation. The market emphasizes the development of innovative drugs that can provide renal protection, delay the onset of end-stage renal disease, and reduce the reliance on dialysis and transplantation. Companies active in the Late-Stage Chronic Kidney Disease drugs market include AstraZeneca, which offers pharmacological treatments tailored to kidney care; Amgen, known for its biologic therapies targeting various complications of CKD; and Sanofi, which provides a comprehensive portfolio of drugs aimed at treating diabetes-related kidney disease and other CKD-related conditions. Other notable companies in this space include GlaxoSmithKline, Johnson & Johnson, and Merck, each contributing research efforts and drug developments to cater to the needs Show Less Read more